Heart rate variabilityCalcium channel blockersCoronary artery diseaseArterial hypertensionObjective To estimate the influence of therapy with amlodipine (A) or lacidipine (L) on heart rate variability (HRV) time and frequency domain parameters in hypertensive patients with stable angina pectoris and ...
heart rate, blood flow, and vascular size within 5-20 min after Nifedipine or Amlodipine injection. For moderate Nifedipine concentrations, these parameters returned to initial values within 2-3 h. Nifedipine showed a rapid reduction in heart rate and blood flow dynamics at a concentration ten ...
Atorvastatin caused no adverse effects on semen parameters, or reproductive organ histopathology in dogs given doses of atorvastatin calcium equivalent to 10, 40, or 120 mg atorvastatin/kg/day for 2 years. 14. Clinical Studies 14.1 Amlodipine for Hypertension Adult Patients The antihypertensive ...
Following administration of therapeutic doses to patients with hypertension, amlodipine produces vasodilation resulting in a reduction of supine and standing blood pressures. These decreases in blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with chron...
In clinical studies in which amlodipine besylate was administered in combination with beta-blockers to patients with either hypertension or angina, no adverse effects on electrocardiographic parameters were observed. In clinical trials with angina patients alone, amlodipine besylate therapy did not alter ...
Table 4 Heart rate recovery and cardiac function parameters Variable AML NIF P-value HRR (beats minÀ1) BNP (pg mlÀ1) LVEF (%) LVMI (g mÀ2) LAD (mm) LVDd (mm) LVDs (mm) PWTH (mm) IVST (mm) 25.3±8.3 27.9±17.3 64.9±4.1 129.3±28.8 40.7±4.6 49.8±4.7 30.1±4.8 9.8...
In adult patients with clinically evident coronary heart disease, atorvastatin is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures
In adult patients with clinically evident coronary heart disease, atorvastatin is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures
While it may not be feasible to measure these parameters directly, close monitoring of clinical signs and radiographic appearance of the lungs is realistic. Therapeutic response is seen as a decrease in cough, return of normal respiratory rate and effort, improved capillary refill time and color (...
In clinical studies in which amlodipine was administered in combination with beta-blockers to patients with either hypertension or angina, no adverse effects on electrocardiographic parameters were observed. In clinical trials with angina patients alone, amlodipine therapy did not alter electrocardiographic ...